JoelStevenLippmanMD

PubMed

• 24 citations
  Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause.
  JoAnn V. Pinkerton, Hadine Joffe, Kazem Kazempour, Hana Mekonnen, Sailaja Bhaskar, Joel Lippman> ;Menopause. 2015 Jan 1
• 16 citations
  Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.
  David Portman, Kazem Kazempour, Hana Mekonnen, Sailaja Bhaskar, Joel Lippman> ;Menopause. 2014 Oct 1
• 93 citations
  Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.
  James A. Simon, David Portman, Hana Mekonnen, Kazem Kazempour, Sailaja Bhaskar, Joel Lippman> ;Menopause. 2013 Oct 1
• 4 citations
  Pharmacokinetic Properties of Once-Daily Oral Low-Dose Mesylate Salt of Paroxetine (LDMP 7.5 mg) Following Single and Multiple Doses in Healthy Postmenopausal Women
  M. Cristina Castelli, Sailaja Bhaskar, Joel Lippman> ;Clinical Therapeutics. 2013 Jun 1
• 72 citations
  Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding.
  Ann J. Davis, Amy Godwin, Joel Lippman, William Olson, Michael E. Kafrissen> ;Obstetrics and Gynecology. 2000 Dec 1
• 33 citations
  Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence
  Geoffrey P. Redmond, Amy Godwin, William Olson, Joel Lippman> ;Contraception. 1999 Aug 1
• 32 citations
  The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 μg ethinyl estradiol versus monophasic levonorgestrel/20 μg ethinyl es...
  Mitchell D. Creinin, Joel Lippman, Scott E. Eder, Amy Godwin, William Olson> ;Contraception. 2002 Sep 1
• 35 citations
  Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipi...
  Patricia J. Sulak, Joel Lippman, Cynthia Siu, Joseph M. Massaro, Amy Godwin> ;Contraception. 1999 Mar 1
• The tolerability of a triphasic norgestimate/EE-containing OC: results from a double-blind, placebo-controlled trial.
  Joel Lippman, Amy Godwin, William Olson> ;Primary Care Update for Ob/gyns. 1998 Jul 1
• 149 citations
  Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.
  Geoffrey P. Redmond, William Olson, Joel Lippman, M.S.P.H. Michael Edwin Kafrissen M.D., Terry M. Jones, Joseph L. Jorizzo> ;Obstetrics and Gynecology. 1997 Apr 1
• Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis.
  Lobo, R. A., Skinner, J. B., Lippman, J. S., Cirillo, S. J.> ;Fertil Steril. 1996 Jun
• Long-term profile of a new progestin.
  Lippman, J.> ;Int J Fertil. 1992
• A review of post-marketing safety and surveillance data for oral contraceptives containing norgestimate and ethinyl estradiol.
  Lippman, J. S., Shangold, G. A.> ;Int J Fertil Womens Med. 1997 Jul 01
• The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne.
  Carmina, E., Godwin, A. J., Stanczyk, F. Z., Lippman, J. S., Lobo, R. A.> ;J Endocrinol Invest. 2002 Oct
• The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris.
  Olson, W. H., Lippman, J. S., Robisch, D. M.> ;Int J Fertil Womens Med. 1998 Nov 01
• Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopeni...
  Grinspoon, S. K., Friedman, A. J., Miller, K. K., Lippman, J., Olson, W. H., Warren, M. P.> ;J Clin Endocrinol Metab. 2003 Aug
• Join now to see all